Pfizer has extended its agreement with Strides Arcolab which will see the Indian firm supply 38 oncology products to the drugs giant for marketing in the European Union, Canada, Australia, New Zealand, Japan and Korea.

A second deal has been signed covering niche sterile injectables for the US market. The new pacts follow an agreement announced in January this year which covered 40 generics, many of which are oncology therapeutics, for the USA.

The companies noted that their agreement now extends to a total of 45 products “around the globe”. David Simmons, head of Pfizer’s Established Products unit, said the collaboration “reinforces our commitment to become a leader in the injectables market.” In May last year, Pfizer signed licensing deals with two other Indian firms Aurobindo Pharma and Claris Lifesciences.

Strides chief executive Arun Kumar said the expanded deal “validates our strategic intent to be a partner of choice to Pfizer and to be a leader in the specialty segment with a focus on specific therapeutic segments such as oncology”. Under the new agreements, financial terms for which were not disclosed, the first of the products is expected to be commercialised in late 2010/early 2011.